Abstract
Introduction
Human papillomavirus (HPV) is one of the most common sexually transmitted infections (STI) worldwide. Nearly all sexually active adults will be infected with one or more HPV types at some point in their lives [1, 2] . More than 40 HPV types are known to infect the ano-genital region, of which at least 13 are classified as oncogenic [2, 3] . HPV infection is often asymptomatic and transient; however, a small proportion of infections persist and cause benign and malignant diseases in men and women [4, 5] . Oncogenic HPV is a necessary cause of cervical cancer and nearly all cervical, approximately 50% of vulvar, and 65% of vaginal cancers, are caused by oncogenic HPV [1, 6] . HPV also causes approximately 40-50% of penile, 85% of anal, 60-70% of oropharyngeal, and 10% of laryngeal cancers [2, [7] [8] [9] [10] . Non-oncogenic HPV types cause genital warts and other benign lesions of epithelial tissues [11] .
In the United States (U.S.), the bivalent and 4-valent HPV vaccines are recommended for routine vaccination for girls at age 11 or 12 years, females age 13 through 26 years, and males age 13 through 21 years if they have not yet received the HPV vaccine [12] . Recently, the Advisory Committee on Immunization Practices (ACIP) added the 9-valent HPV vaccine (9vHPV) to the vaccine recommendations [13] . In 2006, the 4-valent HPV vaccine (4vHPV) was approved for use among women in Brazil [14] , and the vaccine was authorized in Mexico in 2008 [15] . HPV vaccine recommendation for men has yet to emerge in these two countries. The World Health Organization (WHO) issues periodic position papers on vaccine implementation. These papers are reviewed and endorsed by the WHO Strategic Advisory Group of Experts (SAGE) on vaccines and immunization before dissemination to Member States. The first WHO position paper on 4vHPV vaccine was published in April of 2009 [16] . However, this position paper did not recommend HPV vaccination of males, arguing that limited public health resources should be directed toward achieving high coverage (>70%) of HPV vaccination among the primary target population (young adolescent girls) to prevent cervical cancer. In the revised position paper, dated October 2014, WHO upgraded its HPV vaccine recommendations and included secondary target populations (older adolescent females), but once again did not recommend HPV vaccination of males, citing the same a forth mentioned reason [17] . Information on the natural history of HPV infection and serology in men prior to vaccine dissemination is needed to monitor the effectiveness of the vaccine over time.
Although a number of studies have reported seroprevalences of HPV types 6, 11, 16 and 18 in men from different countries [18] [19] [20] [21] [22] [23] , few have examined other HPV types (e.g. 31, 33, 45, 52 and 58) included in the 9vHPV vaccine in the general population. One study included only men who have sex with men (MSM) [24] , another study included men only from the U.S. with an age range of 14-59 years [25] , and two studies using the same study population in the Netherlands examined only the seven high-risk types in the 9vHPV vaccine [26, 27] . Previously, we reported seroprevalences for the 4-valent HPV vaccine types (6, 11, 16 and 18) among men [20] . In this study, we extended our analysis to estimate the seroprevalence of 9vHPV vaccine types and investigated factors associated with the seropositivity in men from three countries (Brazil, Mexico, and U.S.) across a broad age range to report data for the entire adult lifespan and old age.
Methods

Study Population
Study participants included a sub-cohort of 600 men randomly selected from the HPV Infection in Men (HIM) Study. Simple random sampling method was used to select the sub-cohort because performing serology testing for the entire parent cohort was not feasible and costeffective. These 600 men did not report a history of receipt of an HPV vaccine.The HIM Study uses a prospective cohort design to examine the natural history of HPV infections among men in three countries. Detailed descriptions of the study population and procedures have been published elsewhere [28, 29] . Briefly, between July 2005 and September 2009, over 4000 men aged 18-70 years at baseline were recruited from Tampa, Florida, Sao Paulo, Brazil, and Cuernavaca, Mexico. Eligibility criteria included no previous history of penile cancer, anal cancer, ano-genital warts and HIV; no current history or treatment for STIs; no current discharges from the penis or burning sensation during urination; and no history of prior or current participation in HPV vaccine trails. Participants were followed every six months for a median of four years. At enrollment and each study visit, participants completed a computer-assisted self-interviewed questionnaire, provided blood and urine specimens, and underwent a clinical examination. A total of 3,695 HIM Study participants who provided serum specimens and completed the questionnaire at enrollment were eligible to be included in the current study. All participants provided written informed consent. This study was approved by the Institutional Review Boards of the University of South Florida (Tampa, FL, USA), the Ludwig Institute for Cancer Research (Sao Paulo, Brazil), the Centro de Referencia e Treinamento em Doencas Sexualmente Transmissiveis e AIDS (Sao Paulo, Brazil), and the Instituto Nacional de Salud Publica de Mexico (Cuernavaca, Mexico).
Specimens and Data Collection
At the enrollment visit, the HIM Study participants provided detailed information on sociodemographic characteristics, smoking habits, alcohol consumption, medical history, and an extensive sexual behaviors. Archived enrollment serum specimens from 600 participants, collected between July 2005 and September 2009, were tested for seroreactivity to L1 major capsid proteins of the 9vHPV vaccine types (6, 11, 16, 18, 31, 33 , 45, 52 and 58). The antibody detection method was based on a glutathione S-transferase (GST) capture enzyme-linked immunosorbent assay (ELISA), in combination with fluorescent bead technology previously described [30, 31] . To define seropositivity for each of the 9vHPV vaccine types, type-specific cut-off values measured in median fluorescence intensity [MFI] units were applied, as previously described [32] .
Statistical Analysis
Participants in the randomly selected sub-cohort (n = 600) were compared to the full HIM cohort (>4,000 men) on all baseline socio-demographic and sexual behavioral characteristics listed in Table 1 using Chi-square test for categorical variables. Type-specific seroprevalence was calculated as the proportion of men who tested positive for a given HPV type. Four additional categories of 'grouped HPV' (i.e. 9vHPV, high-risk 9vHPV, 5-additional HPV, and lowrisk 9vHPV) were also used as dependent variables in the analyses. '9vHPV' seroprevalence was defined as the proportion of men who were seropositive for at least one of the nine vaccine types. 'High-risk 9vHPV' included men who were seropositive for at least one of the seven oncogenic types (i.e. 16, 18, 31, 33, 45, 52 and 58), '5-additional HPV' included men who were seropositive for at least one of the five oncogenic types not included in the quadrivalent HPV vaccine (i.e. 31, 33, 45, 52 and 58), and 'low-risk 9vHPV' included men who were seropositive for HPV types 6 or 11. Two subjects with inadequate serology results were excluded from all analyses resulting in a final sample size of 598 men. Enrollment sociodemographic and behavioral factors were compared between seropositive and seronegative men with high-and lowrisk 9vHPV using Chi-square test (Table 1) . Seroprevalence estimates were calculated for each HPV type, by country and age group, and compared using Chi-square and Fisher exact tests. The Holm-Bonferroni correction was used to adjust for post-hoc pairwise comparisons of seroprevalence estimates by country. To examine associations between individual and grouped HPV seropositivity and potential risk factors, logistic regression was used and odds ratios (ORs) and their 95% confidence intervals (CI) were estimated. Factors listed in Table 1 were considered for inclusion in the multivariate logistic regression models. Variables were selected using backward stepwise elimination with significance at p 0.1. Country and age were forced into the model due to the study design. To assess the individual contribution of each variable retained in the model at p 0.1, the likelihood ratio test at p<0.05 was performed. The final multivariate models for 9vHPV and low-risk 9vHPV included country, age, smoking, and the lifetime number of male anal sex partners, and in the final model for high-risk 9vHPV, marital status was retained and smoking status was dropped. Multivariate models for individual highrisk HPV types 16, 18, 31, 33, 45, 52 and 58 were adjusted for the same factors as the grouped high-risk 9vHPV model, and multivariate models for individual low-risk HPV types 6 and 11 were adjusted for the same factors as the grouped low-risk 9vHPV model. All analyses were performed in SAS 9.3.
Results
Participants in the randomly selected sub-cohort (n = 600) were similar to the full HIM cohort (>4,000 men) on all baseline sociodemographic and sexual behavioral characteristics listed in Table 1 (p>0.05). The study included 184 participants from the U.S., 200 from Brazil, and 214 from Mexico. None of the 600 men reported a history of HPV vaccine. Participant characteristics by seropositivity to grouped high-and low-risk 9vHPV categories are presented in Table 1 . Significant differences by age, sexual orientation, lifetime number of anal sex partners (LTP), and recent male anal sex partners were observed for seropositivity to high-risk 9vHPV (p<0.05). Mid-adult men (35-44 years) and older men (45-73 years), men who have sex with men (MSM), men who have sex with men and women (MSMW), men with !2 male anal sex partners LTP, and men with !2 recent anal sex partners were more likely to be seropositive for high-risk 9vHPV (p<0.05). Significant differences in seropositivity to low-risk 9vHPV were observed by country, circumcision status, sexual orientation, and number of male anal sex LTP (p<0.05). Grouped and individual type HPV seroprevalence estimates are presented in Table 2 . Overall, 28.3% of men were seropositive for !1 9vHPV type, 14.0% for !1 high-risk 9vHPV types, 11.2% for !1 of the five additional types, and 17.4% for low-risk 9vHPV types 6 and/or 11. Type-specific seropositivity for five individual HPV types was as follows: HPV 31 (4.5%), HPV 33 (1.7%), HPV 45 (3.7%), HPV 52 (2.5%), and HPV 58 (4.7%). for seropositivity with increasing age was observed for grouped high-risk 9vHPV, grouped five-additional types, and some individual HPV types (i.e. 18, 45 and 58).
Factors associated with seropositivity of grouped and specific individual HPV types are presented in Tables 3-5 . In multivariate analyses, adjusting for all other variables in the table, lifetime number of anal sex partners, was significantly associated with seropositivity for grouped and specific individual HPV types (6, 16, 33 and 58 . Compared to never smokers, current smokers were more likely to be seropositive to 9v-HPV, lowrisk 9vHPV and HPV 6. In contrast, compared to men who reported being single/never married, married/cohabiting men were less likely to be seropositive to high-risk 9vHPV, HPV types 18 and 31 (Tables 3-5 ).
Discussion
Previously, we reported seroprevalence of the 4-valent HPV vaccine types (6, 11, 16 and 18) [20] . In this study, we extended our analysis to include five additional HPV types (31, 33, 45, 52 and 58) in the 9vHPV vaccine. Additionally, we investigated factors associated with 9vHPV seropositivity in 598 men recruited from Brazil, Mexico and the U.S. across a broad age range (18- Grouped HPV seroprevalence of nine vaccine types by age group. 9vHPV category included nine vaccine types (6, 11, 16, 18, 31, 33 , 45, 52, and 58). '9vHPV' variable was created, if a man was positive for one or more of the nine vaccine types then the '9vHPV'variable was seropositive otherwise seronegative. 4vHPV category included seropositivity to at least one of the four types of HPV (6, 11, 16 and 18 . Age, lifetime number of male anal sex partners, and smoking were positively associated with seropositivity of grouped and individual HPV types. A recent study [25] in U.S. used competitive Luminex Immunoassay (cLIA) and estimated seroprevalence of 9vHPV vaccine types among men using the National Health and Nutrition Examination Survey (NHANES) data. The seroprevalence estimates for 9vHPV, and 5-additional types in our study were higher than the NHANES study [(28.3% vs. 19 .4%) and (11.2% vs. 6.6%) respectively]. The type-specific seroprevalence estimates of the five additional types were also slightly higher in our study [HPV 31 (4.5% vs. 2.3%), 33 (1.7% vs. 1.6%), 45 (3.7% vs. 0.7%), 52 (2.5% vs. 1.3%), and 58 (4.7% vs. 1.5%). Another study [27] estimated the seroprevalence of five additional types in the Netherlands using virus-like particles (VLP) based serologic assay and reported slightly higher seroprevalence estimates than our study for HPV types 33 (1.7% vs. 6.0%), 45 (3.7% vs. 6.8%) and 52 (2.5% vs.5.2%); and slightly lower estimates for types 31 (4.5% vs. 2.5%) and 58 (4.7% vs. 3.7%). Some of this variation could be partially explained by the differences in serologic assays used, study population, and age distribution across studies. Seroprevalence estimates of grouped and individual 4-valent HPV vaccine types (11, 16 and 18) in our study were considerably lower than the estimates we had previously reported using VLP-based serologic assay, (HPV 11 [3.8% in current study vs. 17.3% in previous study], HPV 16 [3.0 vs. 11.2%], HPV 18 [3.5% vs. 5.8%]) [20] . Whereas important demographic and sexual behavior characteristics such as age, marital status, education, and lifetime number of anal sex partners were similar in both studies, except for country of residence. Compared to previous study, current study had slightly fewer men from U.S. (31% vs. 37%) and slightly higher men OR = unadjusted odds ratio; AOR = adjusted odds ratio; CI = 95% confidence interval; LTP = lifetime partners '-' variable not included in the final adjusted model a. This category included seropositivity to 1 or more of the nine vaccine types (6, 11, 16, 18, 31, 33, 45, 52, 58) b . This category included seropositivity to 1 or more of the high-risk types in the vaccine (16, 18, 31, 33, 45, 52, 58) c. This category included seropositivity to 1 or more of the low-risk types in the vaccine (16, 18) d. Final adjusted models were estimated using backward stepwise elimination method with a significance level of p-value 0.1 for retention. Odds ratios were adjusted for all other variables in the column. from Brazil (33 vs. 30%). Since men from U.S. are less likely, and men from Brazil are more likely, to be seropositive for 4-valent HPV types as shown in both studies, this difference by country of residence is not likely to underestimate the seroprevalence estimates in the current study compared to previously reported. We believe that this variation is due to differences in the serologic assays used in current and previous study, and that the GST L1-based multiplex serologic assay underestimated seroprevalence estimates for 4vHPV types in the current study, except for HPV type 6. Nevertheless, both studies consistently reported that men with multiple lifetime number of anal sex partner, older age, single/never married men, and Brazilians were more likely to be seropositive for 4-valent HPV types.
The positive association of increasing age and high-risk 9vHPV in this study is consistent with previous serology studies in men [18, 20, 33, 34] , and this may reflect the fact that exposure to HPV and antibodies as a response accumulate over time. The positive association of the increasing number of male anal sex LTP with the seropositivity of HPV is also consistent with previous studies [20, 35] and is likely to be explained by i) the increased probability of exposure to HPV types due to multiple sex partners, ii) the highest DNA prevalence of HPV infection and persistence in the anal canal of MSM, and iii) the anatomic site-specific immune response. Studies have shown that HPV infection is common in the anal canal, and its prevalence is higher among MSM than men who have sex with women (MSW) [35] [36] [37] . Recently, emerging evidence showed that HPV infection persists longer in the anal canal of MSM [38] which may explain the highest incidence of HPV-related anal cancers in MSM [39] . Also, it is suggested that the viral antigen is more efficiently detected by the immune system in the mucosal epithelium. Therefore, mucosal epithelium (e.g. anal canal) is more likely to induce immune response to HPV infections compared to keratinized epithelium (e.g. penile skin) [39] [40] [41] . As a result, MSM are more likely to have incident, prevalent, and persistent HPV infections, and potentially may induce greater immune response because of the anatomic location of their infection compared to other sub-groups (e.g. MSW) resulting in high seroprevalence. Current smokers were more likely to be seropositive to low-risk 9vHPV (AOR 1.96; 95% CI: 1.17-3.29). Syrjanen et al. [42] and Dunne et al. [18] also reported a two-fold increased risk of low-risk 9vHPV (6/11) seropositivity for current male smokers. However, Liu et al. [25] did not find an association between smoking and low-risk 9vHPV. In contrast, married/cohabiting men were less likely to be seropositive for high-risk 9vHPV compared to single/never married men. Similar associations have also been reported by other studies previously [27, 43, 44] . This association is likely to be partially explained that single men might have more opportunities of meeting new sex partners compared to married men, therefore, they might have a high probability of exposure to different HPV types. Inclusion of men from three countries across a broad range of ages, detailed information on demographic and sexual history, and the estimation of prevalence based on type-specific antibodies against L1 HPV capsid protein in a single laboratory with one protocol are the strengths of this study. Some limitations should be considered when interpreting the results. This study was a cross-sectional analysis which utilized serology and risk factor data collected at enrollment. HPV prevalence based on antibody response may be affected by waning of antibodies over time and by the seroconversion rate since all infected individuals do not produce an immune response to HPV infections; therefore, prevalence and cumulative exposure of HPV might be underestimated. Seropositivity in our study was measured by GST-based multiplex serologic assay and may not be comparable to estimates measured using other assays. Risk factor data was self-reported. Due to social desirability and recall biases, lifetime number of sex partners may be under-or over-reported. However, the use of computer-assisted self-interviews for sexual behavior data may have minimized the social desirability bias. Despite these limitations, this study provides important data on the distribution of 9-valent HPV vaccine types in a sample of men from three countries. In summary, more than a quarter of men were seropositive for at least one of the nine vaccine type HPV, and MSM were two and half times more likely to be seropositivity to !1 HPV types, indicating the need for HPV immunization in men, and particularly among MSM.
Smoking Status
Never - - - - - - - - Current - - - - - - - - Former - - - - - - - -
Conclusions
Overall, exposure to 9vHPV types was common among men. Seropositivity to 9vHPV vaccine types was associated with older age and the lifetime number of anal sex partners. HPV vaccine could protect against HPV infection, and will reduce the burden of HPV related diseases among men.
